Companies › Eddingpharm (Zhuhai)
1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EDP167 siRNA targeting ANGPTL3 | ANGPTL3 | Phase 2 | Homozygous Familial Hypercholesterolemia (HoFH) | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07489209 | EDP167 | Phase 2 | Homozygous Familial Hypercholesterolemia (HoFH) | Metabolic and endocrine | Mar 2027 |
Visirna Therapeutics HK Regeneron Pharmaceuticals Verve Therapeutics Arrowhead Pharmaceuticals CRISPR Therapeutics
Amorphical ERX Pharmaceuticals Hyundai Pharm Rare Thyroid Therapeutics International River 3 Renal
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.